Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 136-143

  Della Pepa, Chiara ^a   Tonini, Giuseppe ^a   Santini, Daniele ^a   Losito, Simona ^b   Pisano, Carmela ^b   Di Napoli, Marilena ^b   Cecere, Sabrina Chiara ^b   Gargiulo, Piera ^c   Pignata, Sandro ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

BRAF; Chemoresistance; KRAS; Low grade serous; MEK inhibitors; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; K RAS PROTEIN; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; RAS PROTEIN;

ABDOMINAL HYSTERECTOMY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CYTOREDUCTIVE SURGERY; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOLOGY; HUMAN; LOW GRADE SEROUS OVARIAN CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOGENESIS; RETROSPECTIVE STUDY; REVIEW; SALPINGOOOPHORECTOMY; SIGNAL TRANSDUCTION; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84921741703     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.003     Document Type: Review

References (65)

1. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(6):vi24-vi32.
2. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365(26):2473-2483.
3. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365(26):2484-2496.
4. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012, 366(15):1382-1392.
5. Ledermann JA, Perren TJ, Raja FA, Embleton A, Rustin GJS, G. Jayson G et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. ESMO 2013. Abstract 10 . http://www.eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx#.
6. Du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Frielander M et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). ASCO 2013. Abstract LBA5503 . http://www.meetinglibrary.asco.org/content/115898-132.
7. Singer G., Shih I.e.M., Truskinovsky A., Umudum H., Kurman R.J. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003, 22(1):37-41.
8. Singer G., Kurman R.J., Chang H.W., Cho S.K., Shih I.e.M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002, 160(4):1223-1228.
9. Singer G., Oldt R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95(6):484-486.
10. Ho C.L., Kurman R.J., Dehari R., Wang T.L., Shih I.e.M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004, 64(19):6915-6918.
11. Wong K.K., Tsang Y.T., Deavers M.T., Mok S.C., Zu Z., Sun C., et al. BRAFmutationisrareinadvanced-stagelow-grade ovarian serous carcinomas. Am J Pathol 2010, 177(4):1611-1617.
12. Kurman R.J., Vang R., Junge J., Hannibal C.G., Kjaer S.K., Shih I.e.M. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011, 35(11):1605-1614.
13. Kuo K.T.1., Guan B., Feng Y., Mao T.L., Chen X., Jinawath N., et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009, 69(9):4036-4042.
14. Kurman R.J., Shih I.e.M. Molecularpathogenesisandextraovarianoriginof epithelial ovarian cancer shifting the paradigm. Hum Pathol 2011, 42(7):918-931.
15. Mayr D., Hirschmann A., Löhrs U., Diebold J. KRASandBRAFmutationsinovarian tumors: acomprehensivestudyofinvasivecarcinomas, borderlinetumors and extraovarian implants. Gynecol Oncol 2006, 103(3):883-887.
16. Bösmüller H., Fischer A., Pham D.L., Fehm T., Capper D., Von Deimling A., et al. Detectionof theBRAFV600Emutationinserousovarian tumors: a comparative analysis of immunohistochemistry with amutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2013, 44(3):329-335.
17. Grisham R.N., Iyer G., Garg K., DeLair D., Hyman D.M., Zhou Q., et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013, 119(3):548-554.
18. Ardighieri L., Zeppernick F., Hannibal C.G., Vang R., Cope L., Junge J., et al. MutationalanalysisofBRAFandKRASinovarianserousborderline(atypical proliferative)tumoursand associated peritoneal implants. J Pathol 2014, 232(1):16-22.
19. Tsang Y.T., Deavers M.T., Sun C.C., Kwan S.Y., Kuo E., Malpica A., et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 2013, 231(4):449-456.
20. Hsu C.Y., Bristow R., Cha M.S., Wang B.G., Ho C.L., Kurman R.J., et al. Characterization of active mitogen activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004, 10(19):6432-6436.
21. Singer G., Stöhr R., Cope L., Dehari R., Hartmann A., Cao D.F., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005, 29(2):218-224.
22. O'Neill C.J., Deavers M.T., Malpica A., Foster H., McCluggage W.G. Animmunohistochemicalcomparisonbetween low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005 Aug, 29(8):1034-1041.
23. Bonome T., Lee J.Y., Park D.C., Radonovich M., Pise-Masison C., Brady J., et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005, 65(22):10602-10612.
24. Wong K.K., Lu K.H., Malpica A., Bodurka D.C., Shvartsman H.S., Schmandt R.E., et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007, 26(4):404-409.
25. Kaku T., Ogawa S., Kawano Y., Ohishi Y., Kobayashi H., Hirakawa T., et al. Histological Classification of ovarian cancer. Med Electron Microsc 2003, 36(1):9-17.
26. Vang R., Shih I.M., Kurman R.J. Ovarian low grade and high grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009, 16(5):267-282.
27. Silverberg S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynaecol Pathol 2000, 19(1):7-15.
28. Chen V.W., Ruiz B., Killeen J.L., Coté T.R., Wu X.C., Correa C.N. Pathology and classification of ovarian tumors. Cancer 2003, 97(10 Suppl.):2631-2642.
29. Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Gershenson D.M., et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004, 28(4):496-504.
30. Malpica A., Deavers M.T., Tornos C., Kurman R., Soslow R., Seidman J.D., et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007, 31(8):1168-1174.
31. Seidman J.D., Horkayne-Szakaly I., Cosin J.A., Ryu H.S., Haiba M., Boice C.R., et al. TestingoftwobinarygradingsystemsforFIGOstageIIIserous carcinoma of the ovary and peritoneum. Gynecol Oncol 2006, 103(2):703-708.
32. Köbel M., Kalloger S.E., Santos J.L., Huntsman D.G., Gilks C.B., Swenerton K.D. Tumortypeandsubstagepredict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 2010, 116(1):50-56.
33. Motohara T., Tashiro H., Miyahara Y., Sakaguchi I., Ohtake H., Katabuchi H. Long-termoncologicaloutcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma. Cancer Sci 2010, 101(6):1550-1556.
34. Vang R., Shih I.e.M., Salani R., Sugar E., Ayhan A., Kurman R.J. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 2008, 32(11):1667-1674.
35. Matsuno R.K., Sherman M.E., Visvanathan K., Goodman M.T., Hernandez B.Y., Lynch C.F., et al. Agreementfortumorgradeofovariancarcinoma:analysisof archival tissues from the surveillance, epidemiology, and end results residual tissue repository. Cancer Causes Control 2013, 24(4):749-757.
36. Kurman, R.J., Carcangiu, M.L., Herrington, C.S., Young, R.H. WHO Classification of Tumours of Female Reproductive Organs. Fourth Edition. Nov, 2014.
37. Gershenson D.M., Sun C.C., Lu K.H., Coleman R.L., Sood A.K., Malpica A., et al. ClinicalbehaviorofstageII-IVlow-grade serous carcinoma of the ovary. Obstet Gynecol 2006, 108(2):361-368.
38. Shvartsam H.S., Sun C.C., Bodurka D.C., Mahajan V., Crispens M., Lu K.H., et al. Comparisonof theclinicalbehaviorofnewlydiagnosedstagesII-IVlow-gradeserouscarcinomaof the ovary with that ofserousovarian tumors oflowmalignant potential that recur aslow-gradeserouscarcinoma. Gynecol Oncol 2007 Jun, 105(3):625-629.
39. Plaxe S.C. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol 2008, 198(4). 4591.e1-8.
40. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200.
41. Bodurka D.C., Deavers M.T., Tian C., Sun C.C., Malpica A., Coleman R.L., et al. Reclassificationofserousovariancarcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 2012, 118(12):3087-3094.
42. Hannibal A., Vang R., Jette J., Kjaerbye-Thygesen A., Kurman R.J., Kjaer S.K. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 Womed diagnosed in Denmark 1978-2006. Gynecol Oncol 2012, 125(3):655-660.
43. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27(9):1419-1425.
44. Fader A.N., Java J., Ueda S., Bristow R.E., Armstrong D.K., Bookman M.A., et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol 2013, 122(2 Pt 1):225-232.
45. Fader A.N., Java J., Krivak T.C., Bristow R.E., Tergas A.I., Bookman M.A., et al. Theprognosticsignificanceofpre- andpost-treatmentCA-125 in grade 1 serous ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2014, 132(3):560-565.
46. Yancik R., Ries L.G., Yates J.W. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am J Obstet Gynecol 1986, 154:639-647.
47. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
48. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000, 18:106-115.
49. Pignata S., Scambia G., Katsaros D., Gallo C., Pujade-Lauraine E., De Placido S., et al. Carboplatinpluspaclitaxelonceaweekversus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014, 15(4):396-405.
50. Trimbos J.B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003, 95(2):105-112.
51. Schmeler K.M., Sun C.C., Bodurka D.C., Deavers M.T., Malpica A., et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008, 108(3):510-514.
52. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001, 91(12):2329-2334.
53. Schmeler K.M., Sun C.C., Malpica A., Deavers M.T., Bodurka D.C., Gershenson D.M. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol 2011, 121(3):482-486.
54. Gourley C., Farley J., Provencher D.M., Pignata S., Mileshkin L., Harter P., et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneallow-gradeserouscarcinomas. Int J Gynecol Cancer 2014 Nov, 24(9 Suppl 3):S9-S13.
55. Gershenson D.M., Sun C.C., Bodurka D., Coleman R.L., Lu K.H., Sood A.K., et al. Recurrentlow-gradeserous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009, 114(1):48-52.
56. Santillan A., Kim Y.W., Zahurak M.L., Gardner G.J., Giuntoli R.L., Shih I.M., et al. Differencesofchemoresistanceassaybetween invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer. 2007, 17(3):601-606.
57. Gershenson D.M., Sun C.C., Iyer R.B., Malpica A.L., Kavanagh J.J., Bodurka D.C., et al. Hormonaltherapyforrecurrentlow-gradeserouscarcinoma of the ovary or peritoneum. Gynecol Oncol 2012, 125(3):661-666.
58. Smyth J.F., Gourley C., Walker G., MacKean M.J., Stevenson A., Williams A.R., et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007, 13(12):3617-3622.
59. Hatch K.D., Beecham J.B., Blessing J.A., Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68(2):269-271.
60. Papadimitriou C.A., Markaki S., Siapkaras J., Vlachos G., Efstathiou E., Grimani I., et al. Hormonaltherapywithletrozoleforrelapsedepithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004, 66(2):112-117.
61. Bidus M.A., Webb J.C., Seidman J.D., Rose G.S., Boice C.R., Elkas J.C. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecologic Oncology 2006, 102(1):5-7.
62. Schmeler KM, Tao X, Sun CC, Malpica A, Deavers M, Sood A et al. Encouraging responses with bevacizumab in recurrent low-grade serous ovarian cancer. ASCO 2010. Abstract e15503. http://www.meetinglibrary.asco.org/content/44366-74.
63. Grisham R.N., Iyer G., Sala E., Zhou Q., Iasonos A., DeLair D., et al. Bevacizumab shows activity in patients withlow-gradeserousovarianand primary peritonealcancer. Int J GynecolCancer 2014, 24(6):1010-1014.
64. Farley J., Brady W.E., Vathipadiekal V., Lankes H.A., Coleman R., Morgan M.A., et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013, 14(2):134-140.
65. Eisenhauer E.A., Therasseb P., Bogaertsc J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.